NorthStar Medical Technologies Signs Letter of Intent with Clarity Pharmaceuticals to Supply Therapeutic Radioisotope Copper-67 (Cu-67)

News, Press Releases

BELOIT, Wis. and Sydney, Australia – February 11, 2020 – NorthStar Medical Technologies, LLC (NorthStar), a global innovator in the production and distribution of radioisotopes used for medical imaging, and Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, today announced the signing of a Letter of Intent for the commercial supply…

Dr Colin Biggin Moves to Managing Director and CEO, Dr Matthew Harris Resigns from the Board

News, Press Releases

Sydney, Australia 30 October 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that interim-CEO, Dr Colin Biggin, has moved to Managing Director and CEO of the Company, to lead Clarity through the next stages of clinical development and commercialisation. Dr Biggin’s background in radiopharmaceutical development…

Dr Jennifer Rosenthal Appointed Director of Quality and Regulatory Affairs

News, Press Releases

Sydney, Australia 23 October 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Jennifer Rosenthal as Director of Quality and Regulatory Affairs. Jennifer has more than 20 years’ management experience in the biotechnology industry, serving in senior director and executive level roles…

Clarity Receives US FDA response on its Theranostic Investigational New Drug (IND) Application that the study may proceed

News, Press Releases

Sydney, Australia 3 October 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has received a response on its Investigational New Drug (IND) application that the study may proceed from the U.S. Food and Drug Administration (FDA) for a Phase 1-2a theranostic (i.e. diagnostic…

Clarity Pharmaceuticals Announces Submission of Orphan Drug Designation Application for Cu-64 SARTATE™

News, Press Releases

Sydney, Australia 11 September 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has submitted an Orphan Drug Designation (ODD) request with the U.S. Food and Drug Administration (FDA) for 64Cu-SARTATE™, a diagnostic for the clinical management of neuroendocrine tumours (NETs). NETs are a…

Clarity Pharmaceuticals Submits Theranostic Investigational New Drug (IND) Application for Cu-64 SARTATE™ and Cu-67 SARTATE™ to the US FDA

News, Press Releases

Sydney, Australia 3 September 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 1-2a theranostic (i.e. diagnostic and therapy) trial with 64Cu-SARTATE™ and 67Cu-SARTATE™ in…

Clarity Pharmaceuticals Closes $10 million Capital Raising

News, Press Releases

Sydney, Australia 8 May 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has completed its anticipated capital raising of $10,000,005.50. This includes the previously announced strategic investment of $5,000,002.75 from GenesisCare, the largest private provider of cancer treatment in Australia and Europe, an…

Idaho State University: ISU Idaho Accelerator Center announces record production of form of medical isotope copper-67 that will be used in cancer clinical trials

In the News, News

Clarity Pharmaceuticals was featured in Idaho State University News. The Idaho State University Accelerator Center is Clarity’s partner for the production of Copper-67. The article discusses the developments in copper-67 production and the positive effects it has on the expansion of our clinical development program. Read the full article here: https://www.isu.edu/news/2019-spring/isu-idaho-accelerator-center-announces-record-production-of-form-of-medical-isotope-copper-67-that-will-be-used-in-cancer-clinical-trials.html/

Dr Gillies O’Bryan-Tear Joins Clarity Pharmaceuticals’ Board

News, Press Releases

Sydney, Australia 10 April 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O’Bryan-Tear has joined Clarity’s Board following his recent appointment to their Scientific Advisory Board in August 2018 (Clarity Announcement dated 23 August 2018). Dr O’Bryan-Tear joined the pharmaceutical industry in…